These results challenge the interpretation of previous studies, like the EMBARK trial, and support the inclusion of PSMA-PET for patient selection in clinical and trial interventions in prostate ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

Xtandi and Zytiga have been going toe-to-toe in the prostate cancer market for several ... It’s also working on the EMBARK trial in non-metastatic hormone-sensitive patients, which could see ...

The trial evaluated a method (called NeuroSAFE) of preserving the nerves that run through the prostate's outer layers, which are thought to be responsible for producing erections, during prostate ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Two-year data showed significant functional improvements in patients treated with delandistrogene moxeparvovec compared to controls, despite initial trial endpoint failure. The treated group ...

Pocenbrodib is being tested alone and with Zytiga, Lynparza, or Pluvicto in metastatic castration-resistant prostate cancer patients. The trial aims to address resistance to androgen receptor-targeted ...

The trial utilizes the ArteraAI Prostate Test to enable treatment personalization by determining cancer metastasis risk and identifying whether patients may be able to reduce or avoid hormone therapy.